Bone marrow failure
Dyskeratosis congenita
Dyskeratosis congenita is part of a group of genetic telomere biology disorders that can affect bone marrow, lungs, liver and other tissues. A donor transplant can treat severe marrow failure, but it does not correct the telomere disorder throughout the body.
Other names and abbreviations
DC · TBD (broader umbrella) · telomeropathy (broader search term) · telomere maintenance disorder (broader search term) · bone marrow failure · telomere biology disorder · Zinsser-Cole-Engman syndrome
Where transplant fits
Donor transplantation treats severe marrow failure or selected blood malignancies, not the underlying disorder in every organ. Related donors need assessment for the familial telomere disorder; a suitable unrelated donor can be an alternative.
Treatment depends on the exact diagnosis, disease stage, prior treatment and the person’s health. These categories are not estimates of donor demand.
What it is
Telomeres protect the ends of chromosomes. When their maintenance is impaired, some tissues have difficulty renewing themselves. Blood production may fall, and problems can also develop in organs outside the marrow.
Classic dyskeratosis congenita is associated with abnormal nails, changes in skin pigmentation and white patches in the mouth. Not everyone has this combination. Related telomere disorders can first appear as an isolated blood, lung or liver problem.
What causes it
Different genes and inheritance patterns can cause telomere biology disorders, including dominant, recessive and X-linked forms. Some cases have no identifiable variant despite clinical and telomere-length findings.
Features can differ between relatives and across generations. Genetic and specialist telomere testing help clarify the diagnosis and family implications; outward appearance alone cannot establish whether a relative is affected.
What it can do
Marrow failure can cause anemia, bleeding and infection risk. Some people develop myelodysplastic neoplasms or leukemia. Lung fibrosis, liver disease and certain solid cancers are also important complications.
The type and timing of complications vary substantially. A person with mainly blood problems may still need evaluation of the lungs and liver, especially before a transplant.
How it is treated
Treatment addresses the manifestations that are present. It may include transfusions, infection care, selected androgen treatment, organ-specific therapy and ongoing cancer surveillance. Medicines that improve blood counts do not amount to correction of the disorder in all tissues.
Allogeneic transplantation is considered for serious or progressive marrow failure or a blood malignancy. Conditioning needs specialist adaptation because organ vulnerability can increase treatment toxicity.
Donor-derived blood production does not prevent every later complication. Lung, liver and cancer surveillance remain necessary, and pre-existing organ disease can limit the safety or expected benefit of transplantation.
Living with the condition
Care can involve several specialists and repeated assessments even when symptoms are mild. Some people need help with nutrition, dental or oral care, mobility, education or other effects of the condition.
Before transplant, the team assesses current organ function and discusses immediate risks and long-term follow-up. Fertility, infection, graft failure and graft-versus-host disease are relevant alongside the underlying telomere disorder. The practical and emotional effects differ between people.
The donor’s role
A matched relative may be suitable only after assessment excludes the familial telomere disorder. A healthy-looking sibling can share the problem, so HLA matching is only one part of donor selection.
An unrelated donor can provide a transplant option when a suitable family donor is unavailable. That donation may restore blood production; it should not be presented as treatment for every organ affected by dyskeratosis congenita.
Treatment at a glance
- Who it affects
- Presentation ranges from childhood to adulthood. Classic skin, nail and mouth findings may be incomplete or absent in related telomere biology disorders.
- Other treatment options
- Surveillance, transfusion support, selected androgen therapy and organ-specific treatment address manifestations. Lung, liver and cancer monitoring remain important after transplant.
- Cells used for transplantation
- When transplantation is appropriate, the graft contains blood-forming stem cells from a suitable donor. Bone marrow, peripheral blood or cord blood may be selected according to the condition and transplant protocol.
Why the details matter
Existing organ dysfunction may increase transplant risk. The transplant indication for marrow failure must not be generalized to an isolated lung or liver telomere disorder.
Questions to bring to your care team
What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?
Sources and further reading
- Dyskeratosis Congenita and Related Telomere Biology Disorders
GeneReviews, University of Washington / NCBI Bookshelf · Accessed 2026-09-05 - Dyskeratosis congenita
MedlinePlus Genetics, US National Library of Medicine · Accessed 2026-09-05 - Fanconi Anemia and Other Hereditary Bone Marrow Failure Syndromes
EBMT Handbook · 2024-04-11
Understanding can become action.
Some patients need a blood stem cell donor. Others receive different treatment. Wherever your interest began, you can help JBF reach more people who may be able to donate.
Explore the official registry serving where you live. It explains who can join, how registration works and what donation involves.
Find your official registryIf joining is not right for you, a gift to the Jada Bascom Foundation supports education, outreach and referrals to official registries.
Donate to JBFKeep learning
Why matching is hard: an interactive leukemia story
More in bone marrow failure. Sharing a group does not mean sharing a treatment plan.
